RESUMEN
Breath analysis with secondary electrospray ionization (SESI) coupled to mass spectrometry (MS) is a sensitive method for breath metabolomics. To enable quantitative assessments using SESI-MS, a system was developed to introduce controlled amounts of gases into breath samples and carry out standard addition experiments. The system combines gas standard generation through controlled evaporation, humidification, breath dilution, and standard injection with the help of mass-flow controllers. The system can also dilute breath, which affects the signal of the detected components. This response can be used to filter out contaminating compounds in an untargeted metabolomics workflow. The system's quantitative capabilities have been shown through standard addition of pyridine and butyric acid into breath in real time. This system can improve the quality and robustness of breath data.
Asunto(s)
Pruebas Respiratorias , Piridinas , Espectrometría de Masa por Ionización de Electrospray , Pruebas Respiratorias/métodos , Humanos , Espectrometría de Masa por Ionización de Electrospray/métodos , Piridinas/análisis , Metabolómica/métodos , Ácido Butírico/análisis , Gases/análisis , Estándares de ReferenciaRESUMEN
OBJECTIVE: Short-chain fatty acids (SCFAs) are produced when the microbiota in the large intestine cause fermentation of dietary carbohydrates and fibers. These fatty acids constitute the primary energy source of colon mucosa cells and have a protective effect in patients suffering from inflammatory bowel disease (IBD). This study aimed to compare the SCFA levels in the stools of patients with IBD and healthy controls. METHOD: Healthy controls and patients with IBD aged 18 and over were included in the study. Stool samples from all patients and healthy controls were collected, and stool acetic acid, propionic acid, and butyric acid levels were measured using a gas chromatography-mass spectrometry measurement method. RESULTS: In this study, 64 participants were divided into two groups: 34 were in IBD (Crohn disease and ulcerative colitis) and 30 were in healthy control group. When fecal SCFA concentrations of IBD and healthy control groups were compared, a statistically significant difference was observed between them. When the fecal SCFA concentrations of Crohn's disease and ulcerative colitis patients in the IBD group were compared, however, no statistically significant difference was observed between them. Furthermore, when the participants' diet type (carbohydrate-based, vegetable-protein-based and mixed diet) and the number of meals were compared with fecal SCFA concentrations, no statistically significant difference was observed between them. CONCLUSION: In general, fecal SCFA levels in patients with IBD were lower than those in healthy controls. Moreover, diet type and the number of meals had no effect on stool SCFA levels in patients with IBD and healthy individuals.
Asunto(s)
Colitis Ulcerosa , Enfermedad de Crohn , Ácidos Grasos Volátiles , Heces , Humanos , Heces/química , Heces/microbiología , Masculino , Femenino , Adulto , Ácidos Grasos Volátiles/análisis , Ácidos Grasos Volátiles/metabolismo , Colitis Ulcerosa/metabolismo , Colitis Ulcerosa/microbiología , Persona de Mediana Edad , Estudios de Casos y Controles , Enfermedad de Crohn/metabolismo , Adulto Joven , Cromatografía de Gases y Espectrometría de Masas , Dieta , Propionatos/metabolismo , Propionatos/análisis , Ácido Acético/análisis , Ácido Acético/metabolismo , Microbioma Gastrointestinal , Ácido Butírico/análisis , Ácido Butírico/metabolismoRESUMEN
OBJECTIVE: To analyze the concentration of formic acid, propionic acid and butyric acid in gingival crevicular fluid (GCF) of patients with stages â ¢ and â £ periodontitis, and their relationship with periodontitis. METHODS: The study enrolled 37 systemically healthy patients with periodontitis and 19 healthy controls who visited Department of Periodontology, Peking University School and Hospital of Stomatology from February 2008 to May 2011. Their GCFs were collected from the mesial-buccal site of one molar or incisor in each quadrant. Periodontal clinical parameters, including plaque index(PLI), probing depth(PD), bleeding index(BI), and attachment loss(AL). Concentrations of formic acid, propionic acid and butyric acid in the supernatant of the GCFs were analyzed by high-performance capillary electrophoresis (HPCE). The prediction ability of formic acid, propionic acid and butyric acid with the risk of periodontitis and the differences between grade B and grade C periodontitis were analyzed. RESULTS: In this study, 32 patients with stage â ¢ and 5 patients with stage â £ were enrolled, including 9 patients with grade B and 28 patients with grade C. Clinical periodontal variables in the patients with periodontitis were significantly higher than those in the control group (P<0.001). Formic acid was significantly lower in periodontitis than that in the control group [5.37 (3.39, 8.49) mmol/L vs. 12.29 (8.35, 16.57) mmol/L, P<0.001]. Propionic acid and butyric acid in periodontitis were significantly higher than those in the control group: Propionic acid, 10.23 (4.28, 14.90) mmol/L vs. 2.71 (0.00, 4.25) mmol/L, P < 0.001; butyric acid, 2.63 (0.47, 3.81) mmol/L vs. 0.00 (0.00, 0.24) mmol/L, P<0.001. There was no significant difference in formic acid, propionic acid and butyric acid concentrations between grade B and grade C periodontitis (P>0.05). Propionic acid and butyric acid in the deep pocket were significantly higher than in the shallow pocket, while the concentration of formic acid decreased with the increase of PD. Propionic acid (OR=1.51, 95%CI: 1.29-1.75) and butyric acid (OR=3.72, 95%CI: 1.93-7.17) were risk factors for periodontitis, while formic acid (OR=0.87, 95%CI: 0.81-0.93) might be a protective factor for periodontitis. Propionic acid (AUC=0.852, 95%CI: 0.805ï¼0.900), butyric acid (AUC=0.889, 95%CI: 0.841ï¼0.937), f (formic acid, AUC=0.844, 95%CI: 0.793ï¼0.895) demonstrated a good predictive capacity for the risk of periodontitis. CONCLUSION: The concentration of formic acid decrease in the GCF of periodontitis patients, which is a protective factor for periodontitis, its reciprocal have good predictive capacity. However, propionic acid and butyric acid increase, which are risk factors for periodontitis and have good predictive capacity. The concentration of formic acid, propionic acid, and butyric acid vary with probing depth, but there is no significant difference between grade B and grade C periodontitis.
Asunto(s)
Formiatos , Líquido del Surco Gingival , Periodontitis , Propionatos , Humanos , Ácido Butírico/análisis , Líquido del Surco Gingival/química , Ácidos Grasos Volátiles/análisis , Pérdida de la Inserción PeriodontalRESUMEN
Evidence of the relationship between fecal short-chain fatty acids (SCFA) levels, dietary quality and type 2 diabetes mellitus (T2DM) in rural populations is limited. Here, we aimed to investigate the association between fecal SCFA levels and T2DM and the combined effects of dietar quality on T2DM in rural China. In total, 100 adults were included in the case-control study. Dietary quality was assessed by the Alternate Healthy Eating Index 2010 (AHEI-2010), and SCFA levels were analysed using the GC-MS system. Generalised linear regression was conducted to calculate the OR and 95 % CI to evaluate the effect of SCFA level and dietary quality on the risk of T2DM. Finally, an interaction was used to study the combined effect of SCFA levels and AHEI-2010 scores on T2DM. T2DM participants had lower levels of acetic and butyric acid. Generalised linear regression analysis revealed that the OR (95 % CI) of the highest acetic and butyric acid levels were 0·099 (0·022, 0·441) and 0·210 (0·057, 0·774), respectively, compared with the subjects with the lowest tertile of level. We also observed a significantly lower risk of T2DM with acetic acid levels > 1330·106 µg/g or butyric acid levels > 585·031 µg/g. Moreover, the risks of higher acetic and butyric acid levels of T2DM were 0·007 (95 % CI: 0·001, 0·148), 0·005 (95 % CI: 0·001, 0·120) compared with participants with lower AHEI-2010 scores (all P < 0·05). Acetate and butyrate levels may be important modifiable beneficial factors affecting T2DM in rural China. Improving dietary quality for body metabolism balance should be encouraged to promote good health.
Asunto(s)
Diabetes Mellitus Tipo 2 , Dieta , Ácidos Grasos Volátiles , Heces , Población Rural , Humanos , Estudios de Casos y Controles , China/epidemiología , Ácidos Grasos Volátiles/análisis , Ácidos Grasos Volátiles/metabolismo , Femenino , Masculino , Persona de Mediana Edad , Heces/química , Adulto , Factores de Riesgo , Dieta Saludable , Ácido Butírico/análisis , Anciano , Estudios de CohortesRESUMEN
BACKGROUND: Salep is obtained by grinding dried orchid tubers and used as a valuable ingredient in the food industry. Because of the glucomannan content of salep, it is thought to have prebiotic potential. However, there is little information in studies concerning the fermentation characteristics and potential prebiotic properties of salep. The objective of this study was to investigate the effect of salep on bifidobacterial growth by measuring the highest optical density (OD), calculating the specific growth rates, and determining the production of lactic acid and short-chain fatty acids (acetic, propionic, and butyric acid) as a result of bacterial fermentation. RESULT: The OD and pH values obtained in this study showed that salep was utilized as a source of assimilable carbon and energy by the Bifidobacterium species (BS). All Bifidobacterium strains produced lactic, acetic, propionic, and butyric acid, indicating that salep is readily fermented by these bacteria. Salep at 1% (w/v) showed a similar effect on bifidobacterial growth as that promoted by 1% (w/v) glucose used as a traditional carbon source. CONCLUSIONS: Bifidobacterium species can develop in media containing salep as well as in glucose and exhibit the potential to be used as new sources of prebiotics.
Asunto(s)
Polvos/metabolismo , Bifidobacterium/crecimiento & desarrollo , Bifidobacterium/metabolismo , Ácidos Grasos Volátiles/biosíntesis , Propionatos/análisis , Propionatos/metabolismo , Industria de Alimentos , Ácido Acético/análisis , Ácido Acético/metabolismo , Ácido Láctico/análisis , Ácido Láctico/metabolismo , Probióticos , Ácido Butírico/análisis , Ácido Butírico/metabolismo , Ácidos Grasos Volátiles/análisis , Prebióticos , Fermentación , Concentración de Iones de HidrógenoRESUMEN
La deficiencia de succínico semialdehído deshidrogenasa o aciduria gammahidroxibutírica (GHB) es una rara enfermedad autosómica recesiva por alteración en el metabolismo del neurotransmisor inhibidor del ácido gammaaminobutírico. Debido a la deficiencia de esta enzima, se produce acúmulo del metabolito ácido GHB. El espectro clínico es heterogéneo con distintas manifestaciones neurológicas. El tratamiento más utilizado es la vigabatrina, aunque se discute su eficacia. Presentamos el caso de una familia con 2 hijos afectados. El mayor presenta retraso en la adquisición de hitos motores, marcha liberada a los 2 años, dificultad en la psicomotricidad fina, hipotonía axial, normorreflexia y retraso en el lenguaje tanto comprensivo como expresivo. Se evalúa al menor por hipotonía axial. Estudio metabólico: aumento de ácido GHB en orina y en plasma. El diagnóstico se confirma mediante el análisis de mutaciones del gen ALDH5A1. Se trata con vigabatrina en dosis bajas, lo que conduce a una disminución de los niveles de GHB en plasma en más de dos tercios y una evolución clínica favorable (AU)
Succinic semialdehyde dehydrogenase deficiency (gamma-hydroxybutyric aciduria) is a rare neurometabolic disease caused by a deficiency in gamma-aminobutyric degradation, resulting in an increase in gamma-hydroxybutyric acid in biological fluids. The clinical spectrum is heterogeneous, including a variety of neurological manifestations and psychiatric symptoms. The treatment usually used is vigabatrin, but its clinical efficacy is under discussion. We present two affected siblings. The older brother was examined when he was 2.5 years old due to psychomotor and developmental delay, disturbances in motor coordination, axial hypotonia and language disability. His younger brother had mild axial hypotonia when 5 months old. Metabolic studies demonstrated a high plasma and urine concentration of gamma-hydroxybutyric acid. Mutation analysis of the gene ALDH5A1 confirmed the disease. After 1 year of treatment with low-doses of vigabatrin of the older patient, a decrease in gamma-hydroxybutyric acid plasma levels and a slow clinical improvement were observed (AU)